The Company is led by an experienced Board and management team with strong capabilities across biotechnology, clinical development, capital markets and commercialisation.
Our management team is skilled at unlocking value from intellectual property through strategic licensing, partnerships and M&A within the pharmaceutical industry.
Philippa Lewis is a Professional Company Director, Chairperson and Chief Executive with expertise in the medtech, biotech, digital and artificial intelligence (AI) sectors.
Don Brumley has 30 years’ experience as a senior partner of Ernst & Young, Oceania, has extensive experience in IPO’s, transactions and audit.
Chris Elliot has 20 years’ experience as a finance and management executive within both chartered accounting and commercial firms, including PricewaterhouseCoopers, APN Outdoor Group Limited (ASX:APO) and Mandoe Media Pty Ltd.
Dr David Fuller is a qualified medical doctor and pharmacist with over 3 decades of international experience in drug development and commercialization, especially in the therapeutic areas of oncology, renal medicine, neurology and anti-infectives.
Rob McInnes is an intellectual property transactions lawyer and investor in Australian biotech. After working for 30 years in large law and specialist IP firms (18 as a partner), he formed his intellectual property law practice Rob McInnes IP Advisory in 2018.
Philippa Lewis is a Professional Company Director, Chairperson and Chief Executive with expertise in the medtech, biotech, digital and artificial intelligence (AI) sectors.
Philippa has extensive global, commercial and corporate engagement with demonstrated success. Founding over ten start-ups she has led local and North American IPOs, reverse mergers, complex M&A transactions, strategic capital management and multilateral joint ventures within North America, Europe, China and Australia. She was nominated as Zurich Business Leader of the Year and Telstra Business Woman of the Year, and is currently an official company mentor for the Australian Technology Competition as well as an appointed grants assessor for the NSW Government Medtech and Pharma Growth Centre.
Philippa is a Graduate of the Australian Institute of Company Directors, The Institute of Public Companies Canada via Simon Fraser University, and The Adelaide University in respect of Legal Arbitration and is a member of the Australian Institute of Company Directors, The MTAA, The Institute of Arbitrators and Mediators and The Resolution Institute.
Don Brumley has 30 years’ experience as a senior partner of Ernst & Young, Oceania, has extensive experience in IPO’s, transactions and audit. Don has advised and worked with a number of Boards, ranging from some of the largest in Australia to fast growing entrepreneurial and medium sized organisations. Don was the Oceania IPO Leader at Ernst & Young and worked with clients listing on the AUS, US, UK and key Asian stock exchanges. He held positions as Biotech Markets Leader, National Leader of Strategic Growth Markets and on the Board of Partners of Ernst & Young. He is currently a Non-Executive Director of Acrux Limited (ASX: ACR) and previous Board positions include Bio-Gene Technology Ltd (Chair, ASX:BGT) and Murray River Organics Group Limited (ASX: MRG). Don is a Fellow of Chartered Accountants Australia & New Zealand, a member of the Australian Institute of Company Directors.
Rob McInnes is an intellectual property transactions lawyer and investor in Australian biotech. After working for 30 years in large law and specialist IP firms (18 as a partner), he formed his intellectual property law practice Rob McInnes IP Advisory in 2018.
His professional work includes IP and commercialisation strategy in life sciences and biotech, including planning, negotiating and structuring licence agreements and R&D contracts, and conducting diligence on technology ventures. In recent years Rob has turned his attention to investing, training, mentoring, and board and advisory committee roles. He is an active angel investor with a portfolio of around 25 investments, and a mentor or expert-in-residence in multiple start-up programs.
In addition to his career as a lawyer, Rob has a degree in chemistry (protein structure determination) and has been an in-house manager of IP and Technology Transfer with a multinational company.
Dr David Fuller is a qualified medical doctor and pharmacist with over 3 decades of international experience in drug development and commercialization, especially in the therapeutic areas of oncology, renal medicine, neurology and anti-infectives.
Dr. Fuller has a proven track record of creating value across large and small-cap environments and has honed his commercial management, business development, and corporate oversight skills through managing his own businesses, as well as holding senior management and Board roles in both private (EpiAxis, Dimerix, Linear Clinical Research) and ASX listed companies (Dimerix Ltd, Arana Therapeutics, Race Oncology, AdAlta Limited).
David has a strong background in clinical, regulatory and commercial areas, and a successful history of securing multiple INDs/NDAs (or equivalent) with both the FDA and EMA. He has led teams that successfully obtained major market product approvals for Moraxen (cancer pain, UK), Busulfex (haematologic oncology; US Paediatrics and EU Adult indications), Xyrem (narcolepsy; US), and Renagel (chronic kidney disease, EU), including post-approval support. Of note, his regulatory work with Busulfex overcame a major objection from the EMA and also led to a co-authored publication with the FDA on busulfan pharmacokinetics in pediatrics.
Dr. Fuller has designed and executed multiple GCP Phase I-III studies across the US, EU, and Asia for both orphan and major market products. He has extensive experience in product development and commercialization, from Planning, Financing, Pre-clinical, Clinical Development, Regulatory Approval, Product Launch, Pharmacovigilance, and Medical Affairs. He is an effective leader, able to manage complex, multicultural environments and build cross-functional teams.
Chris Elliot has 20 years’ experience as a finance and management executive within both chartered accounting and commercial firms, including PricewaterhouseCoopers, APN Outdoor Group Limited (ASX:APO) and Mandoe Media Pty Ltd.
Chris is a Director of Accension Pty Ltd, which is engaged to provide CFO and Company Secretary services to Imunexus. He has extensive experience across the finance, media and digital technology industries, including executive, finance, commercial, business development and operational roles across these industry sectors.
Chris is a graduate of the Institute of Chartered Accountants of Australia, where he is currently a member.
